One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
News
Pioneering prostate biopsy device wins NIHR award
A new method for extracting prostate biopsies has been awarded a £789,000 Invention for Innovation (i4i) Product Development Award by the National Institute for Health Research (NIHR).
Chief Medical Officer wants genetic tests for all cancer patients
Cancer patients should have access to genetic testing to better tailor treatment for their disease and increase the likelihood of achieving the very best outcomes, concludes a new report by Chief Medical Officer Dame Sally Davies on genomics and its potential for NHS care.
Angle’s ovarian cancer test could beat current standard
UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.
Merck’s Keytruda, Lilly’s Lartruvo available via CDF
Patients with certain forms of lung cancer or sarcoma have now gained access to two new treatment options on the NHS in England after Merck’s Keytruda and Eli Lilly’s Lartruvo were added to the Cancer Drugs Fund.
US Orphan status for Almac’s ovarian cancer drug
In big news for Northern Ireland-headquartered drug discovery group Almac, US regulators have awarded orphan drug status to the firm’s experimental drug for ovarian cancer.
RCGP to work with Manchester on improving GP services
Greater Manchester Health and Social Care Partnership and the Royal College of GPs have signed a memorandum of understanding to deliver a new programme designed to improve GP services across the region.
NHS trust breached data law in DeepMind deal
The UK’s Information Commissioner’s Office says the Royal Free NHS Foundation Trust breached the Data Protection Act when it handed over patient data to Google’s artificial intelligence arm DeepMind.
MPs keen for close collaboration with EMA post Brexit
British MPs say they are keen to secure a close working relationship with the European Union on drug regulation post Brexit to protect patient health and investment in the UK’s life sciences sector.
EU nod for Pfizer’s Besponsa
Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL).
GSK signs drug discovery pact with AI group Exscientia
GlaxoSmithKline has signed a drug discovery pact with Dundee, UK-based artificial intelligence (AI) group Exscientia focused on multiple therapeutic areas.
NICE recommends increased use advanced paramedics
The National Institute for Health and Care Excellence is recommending that the NHS provide more advanced paramedic practitioners (APPs) to help alleviate pressure on emergency departments.
GSK picks third target in Immunocore discovery deal
GlaxoSmithKline has selected a third target in its collaboration with Oxford, UK-based Immunocore to discover multiple novel targets in cancer not addressable with antibody-based technologies.
Raise your profile, enter PharmaTimes Marketer of the Year now
Entering the PharmaTimes Marketer of the Year competition enables you to demonstrate your abilities in front of senior marketing and industry leaders; enjoy a day of fast-paced learning and development in a friendly, welcoming environment; receive personal feedback from judges on your performance and benchmark your skills against your peers.
NICE backs Lilly’s JAK inhibitor Olumiant for RA
A novel treatment option for some patients with rheumatoid arthritis (RA) could soon be routinely available on the NHS, after cost regulators ruled Eli Lilly’s Olumiant to be cost-effective with the inclusion of a confidential patient access scheme.
